Early Administration of Heparin at FMC for PPCI of STEMI Patients
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
Heparin is the first choice of anticoagulation drug for primary PCI of STEMI patients.
However, the priority of use of hepairn in first medical contact or in Cathlab has yet
studied. Previous study revealed early use of antithrombotic drugs could improve patient's
survival. Here we supposed that use of heparin at first medical contact could the TIMI flow 3
grade ratio in STEMI patients and improve patient's survival and/or reduce MACE rather than
in Cathlab.
Phase:
N/A
Details
Lead Sponsor:
Renmin Hospital of Wuhan University
Collaborators:
Jiangxi Provincial People's Hopital The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture The First Affiliated Hospital of Dalian Medical University The First College of Clinical Medical Science, China Three Gorges University Wuhan Central Hospital Xiangyang Central Hospital